Delighted to share this new paper in the European Journal of Cancer: radical local treatment for NSCLC patients with oligoprogression after chemoradiation and durvalumab. 🫁 doi.org/10.1016/j.ejca.2026.…

Looking forward to this wonderful brainstorming session on #SCLC with my excellent colleague and dear friend @a_dingemans , organized in Lausanne on November 13 by @LungSummit @IASLC @peters_solange @Alfdoc2 @SclcSMASHERS linkedin.com/feed/update/urn…

Can T-cell engagers create a "tail of the curve" phenomenon in #SCLC, in a way similar to ICIs? Apparently yes! Long-term Follow-up (22m) of the Dellphi-304 trial as published in @Annals_Oncology and reported in #ESMO2026 by @charlesrudin show 30% pts alive at 2 yrs with tarla compared to 15% with chemo. Sustained disease control for ≥52 weeks was observed in 24.4% versus 4.3%. Confirmatory results of prolonged tarla efficacy, giving hope to our patients @SclcSMASHERS @SCLCYIForum @LungCancerEu @YoungLungCancer @myESMO @IASLC @ASCO annalsofoncology.org/article…

Great guest post by @sarojniraula, discussing his recent @JCO_ASCO editorial with Ian Tannock! @TheWonkologist et al. showed that payments as small as $45 are associated with prescribing decisions involving anticancer drugs. And these drugs can cost tens of thousands of dollars per month! Post here: theoncologyshot.com/p/curren…

#ESMO26: Phase III OptiTROP-Lung06 #ClinicalTrial reports a game-changing 51% reduction in the risk of progression or death with the #ADC sacituzumab tirumotecan added to pembrolizumab in advanced #NSCLC ➡️ ow.ly/QYUT5102qlv #InsightsbyESMO @g_mountzios

Inspired by Science, United by One Goal at ESMO 2026 - Alfredo Addeo @Alfdoc2 oncodaily.com/community/alfr…

Always enjoy discussing the latest data with @high5md - this session on the biggest impact data from #ESMO26, gaining perspectives from Drs. @Griesinger35711 @Alfdoc2 @HendriksLizza @nicogirardcurie @DMSLung @DrRiyazShah @MartinReck2 high5oncology.tv/meeting-cov…

Practice Changing...Or Not? 👉OptiTROP-Lung04 #ESMO26 ✅ New SOC?: “Impressive FINAL OS results from OptiTROP-Lung04 at #ESMO26!” @Alfdoc2 ❌ Or not?: “Global validation and treatment-sequencing questions remain.” @Latinamd KOL Reactions: Practice Changing…Or NOT — 10 ESMO26 Controversies Oncologists Debated on X hubs.ly/Q04CS7qL0

Friends, 🙏 consider voting for @RManochakian who has been a phenomenal educator, clinician and patient advocate! I remember meeting him when I came to @MayoCancerCare FL and his warm and kind personality stayed with me since! @ASCO will be lucky to have him join!

Sometimes important studies fly under the radar and I was rather surprised to see hom many collegue knew the TRIPLEX trial (not yet fully published but not ours, fully published) TheSAKK 15/19 trial phase II trial in ES-SCLC missed its 12-month PFS endpoint but showed encouraging safety with TRT AFTER chemo-IO induction and quite long OS (> 16 months mOS) In contrast, TRIPLEX (#ASCO26) raised major safety concerns with concurrent TRT. Is TIMING the key? And what about TRT in the T-cell engager era? Efficacy remains uncertain, but perhaps the question is not just WHETHER to irradiate, but WHEN @sands_jacob @AndrearicFili @StephenVLiu @DrewMoghanaki 🔗 ejcancer.com/article/S0959-8… #SCLC #LungCancer

📣 Registration for #ELCC27 is now open. Join a focused, multidisciplinary thoracic oncology community to discuss the latest research, exchange perspectives and connect with colleagues from across the field. 🔗 Register now: ow.ly/sglQ50ZZctT #esmomeetings

The M2 metro from Lausanne station stops at CHUV, a short walk from the Agora building, Rue du Bugnon 25A. That is where the International Lung Cancer Summit (ILCS) 2026 meets on 13 November, from 09:45 CET, with every talk also live online. We look forward to welcoming you at the door. ILCS 2026 faculty: @peters_solange @Alfdoc2 @DasMillie11 @HHorinouchi @TelmaSequeiraMD @christine_lovly @dplanchard @PatelOncology @ACortelliniMD @g_mountzios @a_dingemans Registration is open: lungsummit.org/registration/ #ILCS2026 #LungCancer #NSCLC #SCLC

@myESMO 2026: Top trending BsAb oncologists on 𝕏. Explore #ESMO26 insights here: clin.larvol.com/conference/a… #LARVOL #ESMO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #MedicalOncology #ClinicalTrials #BsAbs #BispecificAntibodies | @DrRishabhOnco | @Erman_Akkus | @SuyogCancer | @barriere_dr | @M_Torasawa | @HHorinouchi | @GIMedOnc | @DraMartinezLago | @tompowles1 | @FordePatrick | @GillSharlene | @ChandrakanthMv | @dr_yakupergun | @ErulEnes | @DrYukselUrun

#Voting for @ASCO Election is now open. I am #honored & #humbled to be running as one of the candidates, for the #ASCO #NominatingCommittee, alongside many remarkable talented candidates & GREAT colleagues.   Visit asco.org/election to learn more about the candidates & place your vote!

Fascinating presentation at the HUG Research Day 2026! @hug_ge Augmented reality meets paediatric resuscitation! The InterFACE-AR study explored how augmented reality can support clinical teams during paediatric cardiac arrest, improving coordination and adherence to resuscitation protocols. Promising results from a randomized simulation study, with fewer adrenaline doses administered outside the recommended time window. Well done to the research team! Great to see @hug_ge pushing the boundaries of innovation and translating technology into potentially better patient care! jamanetwork.com/journals/jam…

@myESMO 2026: Most discussed lung cancer trials on 𝕏 and key results. Explore #ESMO26 insights here: clin.larvol.com/conference/a… #LARVOL #ESMO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #MedicalOncology #ClinicalTrials #LungCancer #SCLC #esSCLC #NSCLC #LCSM #ClinicalOncology | @HHorinouchi | @M_Torasawa | @FordePatrick | @RobertoBoreaMD | @GlopesMd | @DrRiyazShah | @FernandoOnco | @StephenVLiu | @tnewsomdavis | @dplanchard | @Latinamd | @Alfdoc2 | @ADesaiMD | @YGaritaonaindia | @g_mountzios

You have my vote 🗳️@RManochakian @MayoClinic for @ASCO Nominating Committee 👇

More thoracic voices on SAFFRON — are you testing for MET overexpression/amplification at osimertinib progression, and how do you weigh OS HR 0.68 against fatal AEs 7% vs 0% while savolitinib remains investigational in the US? @JhanelleGray @DrRoyHerbst @AnaVManana @DrRaviSalgia @LovaSunMD @drtahuahua @ManuelDomine @peters_solange @Alfdoc2 @g_mountzios @TommyJohn00 @DevikaDasMD @HerediaOncologo @ShirishGadgeel @DrJNaidoo @cpeedell

More thoracic voices on Krascendo-1 — how are you counseling pretreated KRAS G12C NSCLC when divarasib remains investigational and approved G12C inhibitors stay the labeled options? @JhanelleGray @DrRoyHerbst @AnaVManana @DrRaviSalgia @LovaSunMD @drtahuahua @ManuelDomine @peters_solange @Alfdoc2 @g_mountzios @tnewsomdavis @TommyJohn00 @DevikaDasMD @HerediaOncologo @DavidHongMD

I couldn’t think of anytime better tbh